Low vitamin B12 levels have been linked to cardiovascular disease, prompting researchers to examine how deficiency affects blood vessels, what clinical trials reveal about supplementation, and which patients might benefit most.
Review: Vitamin B12 and cardiovascular health: mechanisms, clinical evidence, and future directions. Image Credit: CL STOCK / Shutterstock
Low vitamin B12 concentrations are associated with cardiovascular disease, but supplementation has not consistently prevented major cardiovascular events, according to a recent narrative review published in the Nutrition Journal. The strongest evidence of a possible clinical benefit concerns combined B-vitamin therapy for stroke prevention, particularly in populations without mandatory folic acid fortification.
The review draws on laboratory studies, large population studies, and clinical trials to evaluate the role of vitamin B12 in cardiovascular health and whether B12 supplements have cardioprotective activity.
Background
Vitamin B12 is naturally obtained only from animal foods such as meat, fish, eggs, and dairy. Its absorption occurs in multiple steps.
First, gastric acid and digestive enzymes release the vitamin from food. A protein called intrinsic factor (IF) binds B12 and carries it to the ileum to be absorbed. In the blood, only about 20 to 25 percent is in the "active" and usable form, called holotranscobalamin.
Vitamin B12 is key to the activity of two important enzymes. One converts the amino acid homocysteine into another amino acid, methionine, which supports DNA methylation and plays a central role in gene regulation. The other helps break down certain fats and amino acids.
With vitamin B12 deficiency, homocysteine and methylmalonic acid (MMA) build up.
Potential cardiovascular effects of B12 deficiency
The authors describe several mechanisms by which vitamin B12 deficiency might adversely impact cardiovascular health. These include oxidative stress, endothelial dysfunction, hyperhomocysteinemia, and defective methylation processes, all of which are linked to atherosclerosis and vascular damage.
High homocysteine levels (termed hyperhomocysteinemia) are associated with endothelial dysfunction and may contribute to vascular injury and plaque formation. Animal studies have demonstrated increased plaque accumulation with elevated homocysteine levels. In postmenopausal women, hyperhomocysteinemia has been associated with impaired endothelial function, reflected in weaker flow-mediated dilation (FMD), a measure of how well an artery expands in response to increased blood flow.
A related process is the methyl-folate trap. Without B12, methionine synthase cannot use 5-methyl-folate, so folate becomes trapped in a form that cannot readily support other folate-dependent reactions. This impairs DNA synthesis and cell replication, while reduced availability of S-adenosylmethionine (SAM), the body’s main methyl donor, may alter methylation and gene regulation in blood vessels.
The clinical significance of these proposed vascular effects remains uncertain. Another potential pathway involves endothelial dysregulation via reduced nitric oxide sensitivity.
In addition, low vitamin B12 levels are associated with signs of electrical instability in the heart, including electrocardiographic markers of susceptibility to arrhythmias. These findings do not establish that clinical arrhythmias are more common among people with low B12 concentrations.
A case report involving a child with cobalamin C deficiency also described severe myocardial dysfunction. The inherited disorder differs substantially from dietary B12 deficiency, limiting the relevance of this finding to most patients.
Current evidence
Prior observational studies have reported associations between low vitamin B12 levels and stroke, heart failure, markers of arrhythmia susceptibility, atherosclerosis, and death. In one analysis of heart failure patients, high MMA predicted higher all-cause mortality.
Randomized trials have produced less convincing results. For instance, NORVIT and HOPE-2 tested combinations of folic acid, B12 and, in some treatment groups, B6, finding markedly lower levels of homocysteine (about 27 percent reduction) in NORVIT. Yet these interventions did not consistently reduce the incidence of heart attacks, cardiovascular deaths, or total vascular events. HOPE-2 reported fewer strokes among participants receiving combined B-vitamin therapy. NORVIT also hinted at possible harm with the three-vitamin combination.
A Cochrane review of more than 71,000 participants found no meaningful benefit for coronary outcomes.
Across pooled trials, homocysteine-lowering B-vitamin regimens were associated with an approximately 10 percent relative reduction in stroke incidence. Most trials tested vitamin combinations, so the effect cannot be attributed to B12 alone. The strongest benefit was found in regions without folic acid fortification, with a 30 to 35 percent relative fall in stroke incidence in a subgroup analysis, and in people with low folate levels at baseline.
The authors propose that stroke may respond better to homocysteine lowering because small brain vessels rely heavily on healthy endothelium and nitric oxide balance. Heart attacks, by comparison, frequently arise when coronary plaques rupture and trigger blood clots, processes that homocysteine lowering has not been shown to prevent.
High-risk groups
Older adults are at greater risk of B12 deficiency because of reduced stomach acid and poorer absorption. B12 supplementation trials did not find clear evidence of cardiovascular benefit.
Very high B12 levels are also linked to higher mortality, probably because they are markers of underlying illness (such as liver or blood disorders) rather than being harmful in themselves.
Vegetarians and vegans are at high risk of B12 deficiency and elevated homocysteine, which can be corrected by supplementation.
After bariatric surgery, patients face reduced B12 absorption. Liver stores can delay the detection of deficiency for years, so long-term monitoring is necessary. UK NICE guidance recommends considering injections for deficiency caused by some forms of postoperative malabsorption. If oral treatment is chosen, the recommended dose is at least 1 mg daily.
Chronic kidney disease patients on dialysis frequently have high homocysteine levels, which can be lowered by B12-folate supplementation. Trials have not demonstrated a reduction in cardiovascular events. Monitoring B12 status and treating confirmed deficiency remain appropriate, including when anemia is attributable to low B12.
In pregnancy, low B12 levels are associated with preeclampsia, gestational diabetes, lower birth weight, and possible later metabolic problems in children. Adequate intake is recommended. Maternal supplementation can improve B12 status, but evidence for better infant neurodevelopment remains limited and inconsistent.
Testing and treatment
Currently, there are no recommendations for routine population-wide B12 screening for cardiovascular prevention; testing is directed to at-risk populations and people with symptoms of deficiency.
Normal blood B12 levels do not always indicate B12 sufficiency, because total B12 includes forms that cells cannot readily use. With low or borderline levels (roughly 150 to 300 pg/mL), further evaluation of MMA or holotranscobalamin is often performed to confirm functional deficiency. Since homocysteine levels also rise with folate or vitamin B6 deficiency, elevated MMA is a more specific sign of B12 deficiency. Kidney dysfunction can also increase MMA, so the result must be interpreted alongside clinical findings and renal function.
For treatment, a network meta-analysis found that oral, intramuscular, and sublingual B12 all raised B12 concentrations, with no statistically significant differences between the routes. The study also found no significant differences in homocysteine outcomes between routes. Oral doses of 1,000 to 2,000 µg daily are a reasonable first choice for diet- or age-related deficiency. Intramuscular replacement is recommended for pernicious anemia and some causes of irreversible malabsorption; high-dose oral treatment may be appropriate for certain other patients, depending on the cause of deficiency and response to treatment.
Supplements are generally safe, but stronger evidence is needed to support high-dose B12 supplementation as a cardioprotective measure.
Lifestyle factors
Factors that reduce B12 status include heavy alcohol use, smoking, infection with Helicobacter pylori, and long-term use of acid-reducing drugs (proton pump inhibitors) and metformin. Measures to improve B12 status include addressing modifiable risk factors and monitoring people taking medicines associated with deficiency. A balanced diet with adequate B6 and folate, exercise, and weight control also support cardiovascular health.
The potential value of B12 food fortification remains under debate, with implementation generally limited and voluntary.
Genetics
People who carry the MTHFR C677T gene variant may have higher homocysteine, particularly when folate is low. The TCN2 gene also affects B12 transport.
Current guidelines advise against routine genetic testing for cardiovascular prevention, since genotype-guided treatment has not been shown to improve outcomes. The authors call for research to determine optimal B12 ranges, since both low and very high levels are associated with higher mortality.
Conclusion
Low vitamin B12 concentrations are linked to higher cardiovascular risk, but B12 supplements have not reliably prevented heart disease in clinical trials. Treating B12 deficiency has established hematologic and neurological benefits, while the clearest signal for stroke prevention comes from combined B-vitamin therapy in selected populations. These studies do not establish cardiovascular protection from B12 alone.
Holotranscobalamin and MMA can improve detection of functional B12 deficiency when total serum B12 results are inconclusive, but their predictive value for cardiac events is unclear. Future work should focus on advanced biomarkers and on precision approaches that combine blood tests, nutrition status and possibly genetics.
Regarding combined B-vitamin therapy, the authors write:
“Its greatest utility lies in correcting deficiencies and reducing stroke risk in nutritionally vulnerable populations or in those with established cerebrovascular disease. In well-nourished, folate-fortified populations, the incremental cardiovascular benefit is negligible.”
Source:
Journal reference:
Deep learning model automates right ventricular assessment from echocardiograms